MedTrace Logo

A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

NCT00812006 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2024-05-23

Study results available
· View outcomes & findings →

Summary

This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.

Conditions

Interventions

DRUG

rizatriptan benzoate

rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack

DRUG

Comparator: placebo

Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-24
Primary Completion
2009-10-22
Completion
2009-10-22

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812006 on ClinicalTrials.gov